A comprehensive analysis of antidepressant effectiveness has identified escitalopram as the leading medication for preventing patients from experiencing a return of depressive symptoms. According to BBC News, the research examined data from nearly 10,000 people who took various antidepressants for periods of up to one year, with escitalopram demonstrating superior performance in maintaining symptom-free status and reducing treatment discontinuation rates.
Two alternative medications—agomelatine and duloxetine—ranked as the next most effective options, followed closely by fluoxetine, commonly known as Prozac. However, medical professionals emphasise that these findings should not prompt patients currently benefiting from other antidepressants to switch medications, as all these drugs carry distinct advantages and disadvantages depending on individual circumstances.
The underlying research was substantially more extensive than the headline figures suggest. Medical Xpress reported that the network meta-analysis drew on 115 randomised trials involving more than 30,000 participants and compared 20 antidepressants in total, rather than only the dozen or so medications initially described. The study, published in The Lancet Psychiatry with the DOI 10.1016/S2215-0366(26)00326-3, represents one of the most comprehensive evaluations of antidepressant efficacy conducted to date.
Depression remains a widespread condition in the United Kingdom, affecting approximately one in six people. While appropriate treatment and support enable many individuals to recover fully, some experience recurrence of symptoms. Current medical practice recommends that patients continue taking antidepressants for a minimum of six months following the resolution of depression, followed by a gradual tapering process rather than abrupt cessation.
How do SSRIs like escitalopram work?
Medical guidelines typically recommend selective serotonin reuptake inhibitors (SSRIs)—a category that includes escitalopram, sertraline, and fluoxetine—as initial treatment choices for depression. These medications function by increasing serotonin availability in the brain, a neurotransmitter associated with mood regulation. When compared directly to fluoxetine, escitalopram demonstrated superior outcomes: patients taking it showed greater likelihood of symptom improvement that persisted over time and were less inclined to discontinue their medication. Agomelatine, classified as an atypical antidepressant, and duloxetine, a selective noradrenaline reuptake inhibitor (SNRI), also showed strong performance, whereas other medications including sertraline demonstrated no clear advantage.
Prof Eric Ruhé, one of the study's researchers at Radboud University in The Netherlands, emphasised the importance of individualised treatment selection:
Nevertheless, our study can help inform the decisions that prescribers and patients make together: if you start an antidepressant, choose one that not only helps you to get well, but also keeps you well.
What do experts say about changing medication?
Dr Sameer Jauhar, a psychiatrist at Imperial College London, cautioned against over-interpreting the findings for individual patients, noting that
it cannot tell us which antidepressant will work best for an individual patient.He further advised that
I would not interpret these findings as a reason for someone who is responding well to their current antidepressant to change treatment.Prof Allan Young from the Royal College of Psychiatrists similarly stressed that while certain medications showed modest advantages for longer-term outcomes,
the differences are modest and are unlikely to outweigh individual factors such as side effects, previous response and patient preference when deciding on treatment.
What are the side effects of escitalopram?
Like all medications, escitalopram carries potential side effects, which may include sleep disturbances, constipation, and weight gain, though not all users experience these effects. When escitalopram or similar SSRIs prove ineffective or unsuitable, the NHS indicates that doctors may recommend alternative antidepressant classes, such as SNRIs. Older tricyclic antidepressants, including amitriptyline, are now prescribed less frequently due to their side effect profiles.
How long should patients take antidepressants?
The duration of antidepressant treatment requires careful consideration, as recent research has highlighted complexities in determining optimal treatment length. A 2026 review of long-term antidepressant use raised concerns that discontinuation studies may conflate withdrawal symptoms with genuine relapse, and advocated for regular treatment reviews and gradual dose reduction when stopping medication. The balance between continued medication and time spent avoiding depression varies substantially depending on a person's history of depressive episodes. According to a 2026 decision-analysis model, patients with four or five prior episodes required an estimated 1.5 additional years of medication per month of depression averted, whereas those with only one mild episode faced an estimated 11.8 years of continued treatment to prevent one month of depression—a substantially different calculus that should inform individualised treatment decisions.
What support is available beyond medication?
Depression arises from multiple contributing factors and responds to various treatment approaches beyond pharmacological intervention, including psychological therapies and mindfulness-based interventions. The mental health charity Mind emphasises that patients require access to comprehensive information about both the potential benefits and side effects of antidepressants, as well as alternative forms of support. The organisation notes that
It's common for people to need to try more than one medication before they find the right treatment that works for them. And what works may change over time.Patients are encouraged to discuss treatment options thoroughly with their healthcare provider to identify the approach most suited to their individual circumstances, preferences, and medical history.
